Board approves Q1 FY27 results, ESOP grants, and subsidiary restructuring

Board & Shareholder Meetings View source PDF

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-3.4%1-day move

₹530.05

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-3.4-6.2-7.2-7.6-1.5—————

Up moveDown movePending

AI summary

Rossari Biotech board approved Q1 FY27 results. Consolidated revenue rose 28% YoY to Rs 697.2 crore; PAT Rs 35.1 crore. Standalone revenue grew 32% YoY to Rs 482.3 crore; PAT Rs 34.3 crore. Board granted 4,000 ESOP options at Rs 531 each and allotted 2,500 shares at Rs 425. Also approved transferring Saudi arm Rossari International to Rossari Singapore for about Rs 24 crore as internal restructuring.

Likely market impact

Strong Q1 with consolidated revenue up 28% YoY; minor dilution from ESOP grants and immaterial subsidiary restructuring.